Cargando…

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells

Resistance in clear cell renal cell carcinoma (ccRCC) against sunitinib is a multifaceted process encompassing numerous molecular aberrations. This induces clinical complications, reducing the treatment success. Understanding these aberrations helps us to select an adapted treatment strategy that su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rausch, Magdalena, Rutz, Adriano, Allard, Pierre-Marie, Delucinge-Vivier, Céline, Docquier, Mylène, Dormond, Olivier, Wolfender, Jean-Luc, Nowak-Sliwinska, Patrycja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235637/ https://www.ncbi.nlm.nih.gov/pubmed/34208775 http://dx.doi.org/10.3390/ijms22126467

Ejemplares similares

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2021)

FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells
por: Ramzy, George M., et al.
Publicado: (2022)

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2020)

Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets
por: Rausch, Magdalena, et al.
Publicado: (2021)

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance
por: Rausch, Magdalena, et al.
Publicado: (2020)

Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
por: Zoetemelk, Marloes, et al.
Publicado: (2019)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Automated Composition Assessment of Natural Extracts: Untargeted Mass Spectrometry-Based Metabolite Profiling Integrating Semiquantitative Detection
por: Rutz, Adriano, et al.
Publicado: (2023)

Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Blockade of T Cell Contact-Activation of Human Monocytes by High-Density Lipoproteins Reveals a New Pattern of Cytokine and Inflammatory Genes
por: Gruaz, Lyssia, et al.
Publicado: (2010)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis
por: Markowitsch, Sascha D., et al.
Publicado: (2020)

Programmed cell death lives
por: Griffioen, Arjan W., et al.
Publicado: (2022)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Juengel, Eva, et al.
Publicado: (2021)

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
por: Buda-Nowak, Anna, et al.
Publicado: (2017)

Insights on the Structural and Metabolic Resistance of Potato (Solanum tuberosum) Cultivars to Tuber Black Dot (Colletotrichum coccodes)
por: Massana-Codina, Josep, et al.
Publicado: (2020)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
por: Faes, Seraina, et al.
Publicado: (2021)

Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib
por: Berndsen, Robert H., et al.
Publicado: (2019)

Taxonomically Informed Scoring Enhances Confidence in Natural Products Annotation
por: Rutz, Adriano, et al.
Publicado: (2019)

Inventa: A computational tool to discover structural novelty in natural extracts libraries
por: Quiros-Guerrero, Luis-Manuel, et al.
Publicado: (2022)

Spindle cell renal cell carcinoma diagnosed after sunitinib treatment for chromophobe renal cell carcinoma
por: Honda‐Takinami, Ruriko, et al.
Publicado: (2020)

Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the ADAMTS18 gene
por: Xu, Ben, et al.
Publicado: (2021)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

A Rare Case of Sunitinib-Induced Rhabdomyolysis in Renal Cell Carcinoma
por: Liman, Andrew D., et al.
Publicado: (2018)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7pvs0oadnl9hiuooklg115dnim